Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to Buy Sarepta Therapeutics Stock (SRPT)

Buy Sarepta Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Sarepta Therapeutics is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Sarepta Therapeutics employs 1,372 staff and has a trailing 12-month revenue of around $2.4 billion.

Our top picks for where to buy Sarepta Therapeutics stock

Top pick for stock bonuses

  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you open and fund a new account within 45 days
  • Access to a financial planner
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.

Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.

Up to 2% match

  • Trade stocks, ETFs, options, futures and bonds all in one place
  • $0 commissions on stocks, ETFs and equity options, with low contract fees
  • Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.

Top pick for simple, worldwide trading

  • Trade stocks, ETFs, mutual funds, options and cryptocurrency
  • Worldwide stock and options trading
  • Commission-free stocks, ETFs and no transaction fee mutual funds
  • Invest with as little as $1

How to buy Sarepta Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – SRPT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Sarepta Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
12 of 12 results
Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY bullet point infobox
Finder score
Stocks, Bonds, Options, Mutual funds, ETFs, CDs
$0.01
$250
2.83%
Leverage powerful trading tools and low margin rates to trade stocks, options, ETFs, mutual funds and bonds.
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Event contracts, High-yield cash account
$0
$0
3.50%
Get a free stock when you successfully sign up and link your bank account. T&Cs apply.
Trade stocks, options, crypto and more, with advanced trading tools, fractional shares and exclusive perks for Gold members.
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Investments, Retirement, Treasury Bills, High-yield cash account
$0
$0
3.6%
Get up to $10,000 and transfer fees covered when you move your portfolio to Public. T&Cs apply.
Build a diversified portfolio of stocks, bonds, options, ETFs and crypto, with a high-yield cash account and options contract rebates.
SoFi Wealth Management logo
Finder score
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.01%
Get up to $1,000 in stock when you open and fund a new account. T&Cs apply.
Trade stocks, ETFs, and options with zero commissions, invest in IPOs or automate your portfolio, with exclusive perks available through SoFi Plus.
Webull logo
Finder score
Finder score
Stocks, Bonds, Options, ETFs, Futures, Money market funds
$0
$0
3.60%
Deposit or transfer $100,000+ to earn a 4% Match Bonus, or $2,000+ to earn a 3% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&Cs apply.
Trade stocks, ETFs and equity options commission-free, with access to futures, advanced charting tools, a robo-advisor and event trading powered by Kalshi.
Interactive Brokers logo
Finder score
Finder score
Stocks, Options, Mutual funds, ETFs, Cryptocurrency
$0
$0
3.83% Lite
4.83% Pro
Trade in a simulated trading environment and access a wide range of tradable assets.
eToro logo
Finder score
Finder score
Stocks, Options, ETFs, Cryptocurrency, Investments
$0
$0
3.75%
No commission stock, ETF and options trades, with 3.9% interest on your options account balance and no options contract fees. See full disclosure.
Acorns logo
Finder score
Finder score
Stocks, ETFs
$0
$0
N/A
Get a $20 bonus when you set up an account and make your first recurring investment (min. $5). T&Cs apply.
Automate investing with recurring contributions starting at $5 and invest spare change from everyday purchases.
Stash Investments LLC logo
Finder score
Finder score
Stocks, ETFs
$0
$0
0.1%
Get $5 when you sign up and deposit $5. T&Cs apply.
Bank, automate your portfolio or invest in individual stocks and ETFs for as low as $3 per month.
Wealthfront logo
Finder score
Finder score
Stocks, ETFs, High-yield cash account
$0
$500
3.75%
Get a $50 bonus when you sign up and fund a taxable automated investing account with at least $500. T&Cs apply.
Automate your stock and bond portfolio or trade individual stocks for as little as $1 apiece. Plus, earn 3.50% APY on your cash.
JPMorgan logo
Finder score
Finder score
Mutual funds, ETFs
$0
$25,000
N/A
Financial planning, advice and portfolio management. T&Cs apply.
Get ongoing access to an advisory team with personalized financial planning and expert-built portfolios. Provider terms & conditions apply
M1 Finance logo
Finder score
Finder score
Stocks, ETFs, Cryptocurrency
$0
$100
4.00%
Build a custom portfolio of stocks and ETFs with automatic rebalancing. Plus, earn 4.00% APY with a high-yield cash account.
loading
Showing 12 of 12 results

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sarepta Therapeutics stock price (NASDAQ: SRPT)

Use our graph to track the performance of SRPT stocks over time.

Sarepta Therapeutics shares at a glance

Information last updated 2025-12-01.
52-week range$10.42 - $131.31
50-day moving average $20.40
200-day moving average $38.40
Wall St. target price$19.91
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-2.83

Is it a good time to buy Sarepta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sarepta Therapeutics price performance over time

Historical closes compared with the close of $21.34 from 2025-11-28

1 week (2025-11-26) 1.86%
1 month (2025-11-04) 31.73%
3 months (2025-09-04) 15.60%
6 months (2025-06-04) -46.03%
1 year (2024-12-04) -83.13%
2 years (2023-12-04) -75.22%
3 years (2022-12-02) 126.25
5 years (2020-12-04) 158.13

Is Sarepta Therapeutics stock undervalued or overvalued?

Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sarepta Therapeutics's PEG ratio

Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sarepta Therapeutics financials

Revenue TTM $2.4 billion
Gross profit TTM $443.8 million
Return on assets TTM -1.52%
Return on equity TTM -21.37%
Profit margin -11.25%
Book value $12.60
Market Capitalization $2.2 billion

TTM: trailing 12 months

Sarepta Therapeutics share dividends

We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.

Have Sarepta Therapeutics's shares ever split?

Sarepta Therapeutics's shares were split on a 1:6 basis on 11 July 2012 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.

Sarepta Therapeutics share price volatility

Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $10.415 up to $131.31. A popular way to gauge a stock's volatility is its "beta".

SRPT.US volatility(beta: 0.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 0.522. This would suggest that Sarepta Therapeutics's shares are less volatile than average (for this exchange).

Sarepta Therapeutics overview

Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc. ; University of Western Australia; Catalent Maryland, Inc.

Frequently asked questions

What percentage of Sarepta Therapeutics is owned by insiders or institutions?
Currently 4.654% of Sarepta Therapeutics shares are held by insiders and 84.855% by institutions.
How many people work for Sarepta Therapeutics?
Latest data suggests 1,372 work at Sarepta Therapeutics.
When does the fiscal year end for Sarepta Therapeutics?
Sarepta Therapeutics's fiscal year ends in December.
Where is Sarepta Therapeutics based?
Sarepta Therapeutics's address is: 215 First Street, Cambridge, MA, United States, 02142
What is Sarepta Therapeutics's ISIN number?
Sarepta Therapeutics's international securities identification number is: US8036071004
What is Sarepta Therapeutics's CUSIP number?
Sarepta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 037184108

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

More guides on Finder

Go to site